Logo image of KOD

KODIAK SCIENCES INC (KOD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KOD - US50015M1099 - Common Stock

24.56 USD
-0.49 (-1.96%)
Last: 12/10/2025, 8:00:26 PM
24.31 USD
-0.25 (-1.02%)
After Hours: 12/10/2025, 8:00:26 PM
Fundamental Rating

2

Overall KOD gets a fundamental rating of 2 out of 10. We evaluated KOD against 531 industry peers in the Biotechnology industry. The financial health of KOD is average, but there are quite some concerns on its profitability. KOD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KOD had negative earnings in the past year.
KOD had a negative operating cash flow in the past year.
KOD had negative earnings in each of the past 5 years.
In the past 5 years KOD always reported negative operating cash flow.
KOD Yearly Net Income VS EBIT VS OCF VS FCFKOD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

The Return On Assets of KOD (-99.66%) is worse than 75.33% of its industry peers.
Looking at the Return On Equity, with a value of -917.34%, KOD is doing worse than 80.79% of the companies in the same industry.
Industry RankSector Rank
ROA -99.66%
ROE -917.34%
ROIC N/A
ROA(3y)-52.31%
ROA(5y)-39.78%
ROE(3y)-97.26%
ROE(5y)-69.5%
ROIC(3y)N/A
ROIC(5y)N/A
KOD Yearly ROA, ROE, ROICKOD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

KOD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KOD Yearly Profit, Operating, Gross MarginsKOD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

KOD has about the same amout of shares outstanding than it did 1 year ago.
KOD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for KOD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KOD Yearly Shares OutstandingKOD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
KOD Yearly Total Debt VS Total AssetsKOD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -8.70, we must say that KOD is in the distress zone and has some risk of bankruptcy.
KOD has a Altman-Z score of -8.70. This is in the lower half of the industry: KOD underperforms 71.19% of its industry peers.
KOD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.7
ROIC/WACCN/A
WACCN/A
KOD Yearly LT Debt VS Equity VS FCFKOD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 1.78 indicates that KOD should not have too much problems paying its short term obligations.
KOD has a worse Current ratio (1.78) than 79.10% of its industry peers.
KOD has a Quick Ratio of 1.78. This is a normal value and indicates that KOD is financially healthy and should not expect problems in meeting its short term obligations.
KOD's Quick ratio of 1.78 is on the low side compared to the rest of the industry. KOD is outperformed by 77.78% of its industry peers.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78
KOD Yearly Current Assets VS Current LiabilitesKOD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

KOD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.88%.
EPS 1Y (TTM)-12.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

KOD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.89% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-27.93%
EPS Next 2Y-2.06%
EPS Next 3Y1.1%
EPS Next 5Y15.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KOD Yearly Revenue VS EstimatesKOD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
KOD Yearly EPS VS EstimatesKOD Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KOD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KOD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KOD Price Earnings VS Forward Price EarningsKOD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KOD Per share dataKOD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.06%
EPS Next 3Y1.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KOD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KODIAK SCIENCES INC

NASDAQ:KOD (12/10/2025, 8:00:26 PM)

After market: 24.31 -0.25 (-1.02%)

24.56

-0.49 (-1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners83.19%
Inst Owner Change6.4%
Ins Owners5.5%
Ins Owner Change0.03%
Market Cap1.30B
Revenue(TTM)N/A
Net Income(TTM)-217.34M
Analysts75
Price Target21.71 (-11.6%)
Short Float %9.1%
Short Ratio4.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.6%
Min EPS beat(2)-11.61%
Max EPS beat(2)4.42%
EPS beat(4)2
Avg EPS beat(4)-5.48%
Min EPS beat(4)-20.72%
Max EPS beat(4)5.97%
EPS beat(8)5
Avg EPS beat(8)-4.03%
EPS beat(12)7
Avg EPS beat(12)-2.61%
EPS beat(16)9
Avg EPS beat(16)-3.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)71.66%
PT rev (3m)356.12%
EPS NQ rev (1m)-5.98%
EPS NQ rev (3m)-3.81%
EPS NY rev (1m)-3.82%
EPS NY rev (3m)-3.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 54.99
P/tB 54.99
EV/EBITDA N/A
EPS(TTM)-4.12
EYN/A
EPS(NY)-3.5
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS0
BVpS0.45
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -99.66%
ROE -917.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.31%
ROA(5y)-39.78%
ROE(3y)-97.26%
ROE(5y)-69.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -8.7
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)491.62%
Cap/Depr(5y)1852.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.1%
EPS Next Y-27.93%
EPS Next 2Y-2.06%
EPS Next 3Y1.1%
EPS Next 5Y15.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.57%
EBIT Next 3Y-18.62%
EBIT Next 5YN/A
FCF growth 1Y35.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.29%
OCF growth 3YN/A
OCF growth 5YN/A

KODIAK SCIENCES INC / KOD FAQ

Can you provide the ChartMill fundamental rating for KODIAK SCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to KOD.


What is the valuation status for KOD stock?

ChartMill assigns a valuation rating of 0 / 10 to KODIAK SCIENCES INC (KOD). This can be considered as Overvalued.


What is the profitability of KOD stock?

KODIAK SCIENCES INC (KOD) has a profitability rating of 0 / 10.


How financially healthy is KODIAK SCIENCES INC?

The financial health rating of KODIAK SCIENCES INC (KOD) is 5 / 10.


What is the earnings growth outlook for KODIAK SCIENCES INC?

The Earnings per Share (EPS) of KODIAK SCIENCES INC (KOD) is expected to decline by -27.93% in the next year.